<DOC>
	<DOCNO>NCT00760981</DOCNO>
	<brief_summary>To determine subject steroid refractory cGVHD tolerate imatinib mesylate whether cGVHD responds imatinib mesylate .</brief_summary>
	<brief_title>A Pilot Study Imatinib Mesylate Steroid Refractory Chronic Graft Versus Host Disease</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>A . Subject cGVHD require systemic therapy occur &gt; 100 day hematopoietic cell transplant diagnose least one diagnostic feature Appendix A . B . Subject active cGVHD either : 1 . Persistent steroid dependence define inability taper steroid treatment le 0.25 mg/kg/d prednisone equivalent least 3 month 2 . Progression cGVHD sign symptom steroid therapy equivalent prednisone 0.5 mg/kg/d least 1 month . C. Subject least one follow manifestation follow progression disease response imatinib : 1 . Skin change ( rash , sclerosis , fasciitis , ulceration ) 2 . Abnormal eye wetness &lt; = 5 mm measure Schirmer 's test 3 . Oral mucosal change ( erythema , lichenoid change , ulcer , mucoceles ) 4 . Thrombocytopenia ( platelet &lt; 150,000/uL ) . 5 . Abnormal liver function test ( alkaline phosphatase , AST , ALT , total bilirubin &gt; ULN ) . 6 . Bronchiolitis obliterans ( diagnose &gt; 5 % annual decline FEV1 low posttransplant FEV1/FVC &lt; 0.8 appropriate CT scan lung biopsy , see Appendix A detail ) D. Subject may previously receive immunosuppressive therapy cGVHD . Continuing treatment steroid one none follow allow : cyclosporine , tacrolimus , sirolimus , mycophenolate mofetil , extracorporeal photopheresis . E. Subject fix dose steroid fix dose steroid one immunosuppressant ( cyclosporine , tacrolimus , sirolimus , mycophenolate mofetil , extracorporeal photopheresis ) &gt; = 30 day start imatinib . F. Subject life expectancy &gt; = 6 month . G. Subject ability understand willingness sign write informed consent document . H. Subject Karnofsky performance status^3 50 % ( Appendix B ) . I . Subject Â³ 18 year age . J . If female reproductive potential ( define least 1 menstrual period past 12 month ) , subject must negative pregnancy test perform &lt; = 7 day start study drug . K. If female reproductive potential , subject agrees use contraception duration trial . L. Subject total bilirubin &lt; 1.5X ULN . M. Subject aspartate transaminase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase &lt; 2.5X ULN . N. Subject absolute neutrophil count &gt; 500/uL ( growth factor supplementation allow ) . O . Subject hematocrit &gt; 26 % ( transfusion support allow ) . P. Subject platelet count &gt; 20,000/uL . A . Subject receive another investigational agent &lt; = 30 day start study drug . B . Subject ongoing , intercurrent illness infection responsive antibiotic , antiviral medicine , antifungal medicine . C. Subject progressive malignant disease . D. Subject secondary malignancy effectively treat within past 5 year ( except localize basal cell squamous cell carcinoma ) . E. Subject imatinib intolerance allergy . F. Subject breastfeeding . G. Subject willing comply treatment response evaluation . H. Subject receive allogeneic cell product ( include DLI hematopoietic cell boost ) &lt; = 100 day start study drug . I . The subject 's steroid and/or immunosuppressant dose change &lt; = 30 day start study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>